Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03735446 · ClinicalTrials.gov registry record · Phase 1
Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT03735446: Clinical Trial Phase 1 study, sponsored by Dana-Farber Cancer Institute.
NCT03735446 is a Phase 1 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03735446, a Phase 1 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This research study is studying a targeted therapy combined with chemotherapy as a possible treatment for acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS). The drugs involved in this study are: * Prexasertib (LY2606368) * Mitoxantrone * Etoposide * Cytarabine
Primary Outcome
Toxicities occurring following administration of protocol therapy, measured using CTCAE 5.0 criteria.
Interventions
- DRUG Etoposide
- DRUG Cytarabine
- DRUG Mitoxantrone
- DRUG Prexasertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-01-18 |
| Est. Completion | 2019-03-29 |
| Phase | Phase 1 |
Why NCT03735446 stopped before completion
NCT03735446 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 4 interventions - of which Etoposide is the first listed.
NCT03735446 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03735446 about?
NCT03735446 is a clinical study titled "Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial". This research study is studying a targeted therapy combined with chemotherapy as a possible treatment for acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS). The drugs involved in this study are: * Prexasertib (LY2606368) * Mitoxantrone * Etoposide * Cytarabine
What is the current status of trial NCT03735446?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2019-01-18. Estimated completion is 2019-03-29.
What interventions are being tested in trial NCT03735446?
The interventions under investigation include: Etoposide (DRUG), Cytarabine (DRUG), Mitoxantrone (DRUG), Prexasertib (DRUG).
Who is sponsoring clinical trial NCT03735446?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03735446's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI